W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies
X

Transparency Council meeting 19/2022 on 16/05/2022

The agenda includes:

Preparation of opinions on drug technologies evaluated for inclusion in the list of highly innovative drug technologies.

Preparation of positions on the evaluation of drugs:

  • Tysabri (natalizumab) under the drug program: “Treatment of multiple sclerosis (ICD-10 G35) with natalizumab administered intravenously”,
  • Tysabri (natalizumab) under the drug program: “Treatment of multiple sclerosis (ICD-10 G35) with natalizumab administered subcutaneously”,
  • Granulox (hemoglobin spray) in the indication: treatment of chronic wounds, such as: venous ulcers of the lower extremities, arterial ulcers of the lower extremities, mixed ulcers of the lower extremities, ulcers in diabetic foot syndrome, secondary healing of postoperative wounds, decubitus ulcers; treatment of wounds with diffuse necrosis and infected wounds after appropriate treatment.

Preparation of an opinion on the draft health policy program of the local government unit: “Health policy program for therapeutic rehabilitation of residents of the Kalisz Pomorski municipality aged 60+ for 2022-2026”.

  • carbamazepineum for the indication: neuralgia and neuropathic pain other than those specified in the CLP,
    lacosamide for the indication: add-on therapy in patients below 16 years of age with focal epilepsy with no control or intolerance to treatment after at least three add-on therapy attempts (ICD-10: C96.2),
  • posaconazole for the indication: chronic granulomatous disease characterized by a high incidence of fungal organ infections; myelodysplastic syndrome (MDS) in children under 18 years of age being prepared for hematopoietic cell transplantation; post hematopoietic stem cell transplantation in children under 18 years of age – secondary antifungal prophylaxis targeting pre-existing fungal infections until stable implantation and completion of immunosuppressive therapy; chronic granulomatous disease characterized by a high incidence of fungal organ infections with intolerance to fluconazole and/or itraconazole; myelodysplastic syndrome (MDS) in children over 13 years of age in preparation for hematopoietic stem cell transplantation. post hematopoietic stem cell transplantation in children over 13 years of age with fluconazole and/or itraconazole intolerance – secondary antifungal prophylaxis, targeting pre-existing fungal infections, until stable implantation and completion of immunosuppressive therapy,
  • capecitabiunum for the indication: malignant neoplasm of the pancreas as part of complementary postoperative treatment of the pancreas in combination with gemcitabine (ICD-10: C25),
  • sunitinbum for the indication: treatment of soft tissue sarcomas (ICD-10 C48, C49): alveolar soft part sarcoma in locally advanced or generalized stages when radical surgical treatment is not possible in patients 18 years of age and older,
  • peginterferonum alfa-2a for the indication: C92.1 chronic myeloid leukemia.